NCT00629525View on ClinicalTrials.gov

RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

December 31, 2009

Study Completion Date

January 31, 2010

Conditions
Hormone Refractory Prostate Cancer
Interventions
DRUG

RAD001

RAD001 at a dose of 10 mg PO daily

Trial Locations (1)

27710

Duke University MEdical Center, Durham

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Daniel George, MD

OTHER